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Many studies have proposed methods to detect adverse drug reactions induced by 
taking two drugs together. These suspected adverse drug reactions can be discovered 
through post-market drug safety surveillance. Post-market drug safety surveillance relies 
on spontaneous reporting data including ADR reports and prescription information. Most 
previous studies have applied statistical models to real world data and compared the 
performance. In this article, we assess the performance of various detection methods by 
implementing simulations under various conditions. This allows us to determine which 
situation each of the methods is most useful for. In addition, we summarize and generalize 






                                                                            




Polypharmacy, the use of multiple medicines has increased as the average life 
expectancy and the prevalence of multimorbidity has increased. Adverse events (AEs) 
caused by the administration of many drugs at the same time are therefore a serious concern. 
These suspected adverse drug reactions (ADRs) due to drug-drug interaction (DDI) can be 
discovered through post-market drug safety surveillance (PMS). Spontaneous reporting 
systems (SRSs) are databases used for PMS that include ADR reports and prescription 
information (e.g, sex, age, date, quantity, etc). By investigating SRS databases using data 
mining tools, we can identify signals and prevent the potential ADRs induced by DDI. 
Generally, quantitative DDI signals refer to excessive risk for a combination of two drugs 
compared with the risks for the individual drugs. However, the criteria used in each method 
to define signals are different and have various pros and cons. 
Many previous studies have proposed approaches to detect signals indicating drug-
drug interactions as well as single-drug adverse reactions. Nor𝑒́n et al. (2008) proposed 
the 𝛺  shrinkage measure to screen for disproportional reporting indicative of 
suspected drug-drug interaction. Gosho et al. (2017) proposed the chi-square statistic as 
a statistical criterion for detecting drug-drug interaction signals and compared this method 
with Nor 𝑒́ n’s using a simulation study. The proportional reporting ratio (PRR) 
proposed by Evan et al. (2001) was used to detect signals indicating single-drug 
reactions, then was extended for drug-drug interactions by Wang, X. et al. (2020). The 
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concomitant signal score (CSS), proposed by Noguchi et al. (2020), is an improved 
detection method using the PRR. Thakrar et al. (2007) proposed the additive and 
multiplicative model. 
 Many previous studies applied the statistical models to real world data, then 
compared the performance. A few studies have used simulation to evaluate the performance 
of various detection methods. The main purpose of this study is to assess the performance 
of various detection methods and to determine which situation each of methods is most 
useful for. In addition, by comparing the results, we can summarize and generalize the 
characteristics of each method.  
Thus, in section 2, we provide an overview of existing methods. In section 3, we 
implement simulations in order to evaluate each method in terms of sensitivity and false 
positive rate. In section 4, we compare the performance of the signal detection algorithms 
for DDI in terms of sensitivity, false positive rate. In section 5,  we applied DDI signal 
detection methods to the Korea Adverse Event Reporting System (KEARS) data (2017 – 
2019) from the Korea Institute of Drug Safety and Risk Management (KIDS).
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2. A review of drug-drug interaction signal detection 
methods 
2.1 Notation 
The methods are fundamentally based on the observed frequencies table presented in 
Table 1. Table 1 shows reported frequencies according to exposure status and adverse event 
(AE) status. Let 𝑓00  denote the relative reporting rate in the absence of both Drug 1 and 
Drug 2. Similarly, 𝑓10, 𝑓01 , and 𝑓11 are, respectively, the relative reporting rate (i) with 
Drug 1 but not Drug 2, (ii) with Drug 2 but not Drug 1, and (iii) with concomitant use of 
the two drugs. 
Table 1. Observed frequencies table for drug-drug-AE combinations 
Exposure status AE status  
Relative reporting rate 
 Drug1 Drug2 Yes No 
No No a b 𝑓00 = 𝑎/(𝑎 + 𝑏) 
Yes No c d 𝑓10 = 𝑐/(𝑐 + 𝑑) 
No Yes e f 𝑓01 = 𝑒/(𝑒 + 𝑓) 
Yes Yes g h 𝑓11 = 𝑔/(𝑔 + ℎ) 
 
2.2  𝛀 shrinkage method 
Nor?́?n et al. proposed the Ω shrinkage method. The Ω shrinkage method compares 
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the observed reporting rate 𝑓11  with its expected value 𝐸[𝑓11]  estimated under the 
assumption that there is no interaction between the two drugs. The estimator 𝑔11 of 
𝐸[𝑓11] is defined as: 
 




















We define N=g as the observed report frequency, and E=𝑔11 ⋅ (𝑔 + ℎ) as the expected 







where 𝛼 represents the tuning parameters determining shrinkage strength. Generally,  𝛼 
is set to 0.5. The lower limit of the 95% confidence interval for Ω can be estimated as 
follows: 
 





where 𝜙(0.975) is the 97.5th percentile of the standard normal distribution. The criterion 
Ω025 > 0 is used to determine the drug-drug interaction (DDI) signal. 
2.3 Chi-square statistics method 
Gosho et al. (2017) proposed the chi-square statistic model in order to reduce the false 
positive rate when events are rare. The measure of the chi-square statistic method 𝑋 is the 
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square root of the chi-square test statistic with a correction term.  
 
X =




The threshold 𝑋 > 2 and 𝑋 > 2.6 is set for identifying DDI signals. These cutoff values 
are set based on the 95th and 99th percentiles, respectively, of the chi-square distribution 
with one degree of freedom.  
2.4 Proportional reporting ratio (PRR) 
The proportional reporting ratio is commonly used in disproportionality analysis to 
detect adverse event induced by a single drug. PRR is the ratio of observed reporting rate 
with or without a drug. PRR is extended to drug-drug interactions. First, 𝑃𝑅𝑅𝐷1 for Drug1 
and 𝑃𝑅𝑅𝐷2 for Drug2 are defined as: 
 
𝑃𝑅𝑅𝐷1 =
(𝑐 + 𝑔)/(𝑐 + 𝑑 + 𝑔 + ℎ)





(𝑒 + 𝑔)/(𝑒 + 𝑓 + 𝑔 + ℎ)
(𝑎 + 𝑐)/(𝑎 + 𝑏 + 𝑐 + 𝑑)
 
(6) 




(𝑎 + 𝑐 + 𝑒)/(𝑎 + 𝑏 + 𝑐 + 𝑒 + 𝑓)
 
(7) 
The lower limit of the 95% confidence interval for PRR is defined as: 
 𝑃𝑅𝑅025 = 𝑒
ln𝑃𝑅𝑅−1.96𝑆𝐷 (8) 












, the SD for Drug2 
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. The signal detection criterion is to compare 
the lower limit of the 95% confidence interval for a single drug and drug-drug pairs. If 
𝑃𝑅𝑅025𝐷1𝐷2 > max (𝑃𝑅𝑅025𝐷1 ,𝑃𝑅𝑅025𝐷2), then the drug pair is considered to be a signal 
of DDI. 
2.5 Concomitant signal score (CSS) 
The concomitant signal score, proposed by Noguchi et al. (2021), was shown to 
improve the combination risk ratio (CRR), a DDI detection method using PRR. The 
weakness of CRR is that the lower limit of the 95% CI of 𝑃𝑅𝑅𝐷1𝐷2 overlaps with the 
upper limit of the 95% CI of 𝑃𝑅𝑅𝐷1or 𝑃𝑅𝑅𝐷2. This is because adverse event reports 
involving individual drugs are more common than reports concerning the concomitant use 
of two drugs. The concomitant signal score is the ratio of 𝑃𝑅𝑅025𝐷1𝐷2 and the maximum 
value between  𝑃𝑅𝑅975𝐷1 and 𝑃𝑅𝑅975𝐷2.  
 





The signal detection criteria are (1) 𝑃𝑅𝑅025𝐷1𝐷2 > 1, (2) CSS > 1. 
2.6 Additive model 
Thakrar et al. proposed the additive model for the detection of DDI signals. The 
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additive model assumes that the risk associated with a drug adds to the background risk. 
Under the additive assumption, no interaction is established when the excess risk associated 
with the drug combination is the same as the sum of the excess risks associated with each 
exposure in the absence of the other. The risk difference is defined as  𝑅𝐷𝐴𝐵 = 𝑓11 − 𝑓00, 
𝑅𝐷𝐴 = 𝑓10 − 𝑓00 , and 𝑅𝐷𝐵 = 𝑓01 − 𝑓00  . When 𝑅𝐷𝐴𝐵 > 𝑅𝐷𝐴 + 𝑅𝐷𝐵  , the signal is 
detected. That is, 𝑓11 -𝑓10 -𝑓01  𝑓00  statistically significantly greater than 0 indicate a 
positive interaction. Therefore, we fit the linear probability model and test the interaction 
term. 
 𝑟𝑖𝑠𝑘 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡 = 𝛼 + 𝛽1𝐷𝑟𝑢𝑔1 + 𝛽2𝐷𝑟𝑢𝑔2+ 𝛽3𝐷𝑟𝑢𝑔1 ∗ 𝐷𝑟𝑢𝑔2 (10) 
When 𝛽3  is statistically significantly greater than 0, there is a potential DDI. 
2.7 Multiplicative model 
Thakrar et al. proposed the multiplicative model for the detection of DDI signals. The 
multiplicative model assumes that the risk associated with a drug multiplies with the 










When 𝑅𝑅𝐴𝐵 > 𝑅𝑅𝐴 × 𝑅𝑅𝐵  , the signal is detected. When 
𝑅𝑅𝐴𝐵
𝑅𝑅𝐴×𝑅𝑅𝐵
  is statistically 
significantly greater than 1, there is a signal indicating a potential DDI. Likewise, we 
implement the log linear regression to test the interaction term.  
 𝑙𝑜𝑔 (𝑟𝑖𝑠𝑘 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡) =  𝛼 + 𝛽1𝐷𝑟𝑢𝑔1+ 𝛽2𝐷𝑟𝑢𝑔2 + 𝛽3𝐷𝑟𝑢𝑔1 ∗ 𝐷𝑟𝑢𝑔2 (11) 
When 𝛽3  is statistically significantly greater than 0, there is a potential DDI. 
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3. Simulation study 
We generated data from a binomial distribution in each row of Table 1. The incidence 
probability of an adverse event f was set differently for each scenario. The data generation 
was repeated 3,000 times in each setting. We implemented simulations under the additive 
assumption and multiplicative assumption. 
 In scenario 1, we assumed that there is no interaction under the additive assumption 
to evaluate the false positive rate. (1-1) assumed that there is no effect of each single drug 
and no interaction; (1-2) assumed that there is an effect of Drug2, but no interaction; (1-3) 
assumed that there is an effect of Drug1 and Drug2, but no interaction; and (1-4) assumed 
that the effect of Drug2 is greater than that of Drug1. 
 In scenario 2, we assumed that there is a positive interaction to evaluate sensitivity. 
(2-1) assumed that there is an interaction but no effect of each single drug; (2-2) assumed 
that there is an effect of Drug2, and interaction; (2-3) assumed that there is an effect of 
Drug1 and Drug2, and an interaction; and (2-4) assumed that the effect of Drug2 is greater 
than that of Drug1. 
In scenario 3, we assumed that there is no interaction under the multiplicative 
assumption to evaluate the false positive rate. Following the structure of scenario 1, 
scenarios (3-1), (3-2), (3-3), and (3-4) were implemented. 
In scenario 4, we assumed that there is a positive interaction under the multiplicative 
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assumption to evaluate sensitivity. Following the structure of scenario 2, scenarios (4-1), 
(4-2), (4-3), and (4-4) were implemented. 
 
4. Results 
4.1 Additive assumption 
The false positive rate of the 𝛺 method ranged from 0.001 to 0.055. The false positive 
rate of the chi-square method with threshold=2 was similar to that of the  𝛺 method: 
between 0.001 and 0.066. The false positive rate of the chi-square method with 
threshold=2.6 showed the smallest variation, ranging from 0.000 to 0.029, while the PRR 
method showed a wide range of false positive rate, ranging from 0.006 to 0.127.  
The 𝛺 method and the chi-square method with threshold=2 controlled the false 
positive rate below 0.05 and had high sensitivity in most scenarios. In particular, when the 
number of events is small (g < 2), the chi-square method has a higher sensitivity than the 
𝛺 method. The CSS method showed the lower false positive rate than the 𝛺 method or 
the chi-square method, but it also showed the lower sensitivity. This may be due to the 
lower threshold for the measure of the CSS method to reach an interaction. Comparing the 
additive and the multiplicative model, when there is no effect of each single drug or there 
is an effect of Drug2 only (scenarios (2-1) and (2-2)), the multiplicative model showed the 
higher sensitivity than the additive model. On the other hand, when there is an effect of 
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Drug1 and Drug2 (scenarios (2-3) and (2-4)), the additive model showed the higher 
sensitivity than the multiplicative model. Scenarios (2-3) and (2-4) are more realistic 
conditions. Indeed, when we applied both models to real world data, the additive model 
detected a signal of DDI that the multiplicative model couldn’t detect.  
 Comparing scenarios (2-3) and (2-4), most methods except the multiplicative model 
showed the higher sensitivity in the scenario (2-4). That is, when the difference between 




Table 2. False-positive rate in simulation scenario 1 
Incidence probability for AE(%) False positive rate 
Ω shrinkage 
method 
𝑋2  statistics method PRR CSS Additive Multiplicative 
𝑓00  𝑓10 𝑓01  𝑓11 g E  Χ𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑=2 Χ𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑=2.6     
Scenario 1-1 
0.005 0.005 0.005 0.005 1.5 1.4 0.008 0.013 0.005 0.012 0.003 0.001 0.065 
0.05 0.05 0.05 0.05 6.0 7.2 0.007 0.006 0.002 0.017 0.005 0.020 0.055 
0.5 0.5 0.5 0.5 50.9 55.3 0.001 0.001 0.000 0.010 0.004 0.029 0.037 
Scenario 1-2 
0.001 0.001 0.005 0.005 1.5 0.9 0.031 0.049 0.025 0.013 0.002 0.001 0.003 
0.01 0.01 0.05 0.05 6.0 6.5 0.032 0.028 0.008 0.013 0.008 0.016 0.027 
0.1 0.1 0.5 0.5 51.0 53.4 0.003 0.003 0.000 0.006 0.002 0.031 0.026 
Scenario 1-3 
0.001 0.003 0.003 0.005 1.5 0.8 0.039 0.066 0.029 0.083 0.004 0.001 0.002 
0.01 0.03 0.03 0.05 5.9 5.1 0.054 0.048 0.015 0.127 0.051 0.011 0.000 
0.02 0.05 0.05 0.08 8.9 8.1 0.055 0.049 0.017 0.114 0.074 0.019 0.000 
Scenario 1-4 
0.002 0.003 0.006 0.007 1.7 1.1 0.045 0.058 0.029 0.029 0.005 0.001 0.008 
0.002 0.003 0.015 0.016 2.6 2.0 0.046 0.053 0.023 0.023 0.005 0.006 0.002 




Table 3. Sensitivity in simulation scenario 2  
Incidence probability for AE(%) Sensitivity 
Ω shrinkage 
method 
𝑋2  statistics method PRR CSS Additive Multiplicative 
𝑓00  𝑓10 𝑓01  𝑓11 g E  Χ𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑=2 Χ𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑=2.6     
Scenario 2-1 
0.001 0.001 0.001 0.005 1.5 0.5 0.090 0.205 0.112 0.185 0.013 0.005 0.042 
0.01 0.01 0.01 0.05 6.0 2.1 0.581 0.584 0.436 0.567 0.506 0.493 0.764 
0.1 0.1 0.1 0.5 51.0 13.2 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
Scenario 2-2 
0.001 0.001 0.002 0.005 1.5 0.6 0.075 0.140 0.084 0.094 0.011 0.002 0.024 
0.01 0.01 0.02 0.05 6.0 3.0 0.332 0.329 0.218 0.387 0.244 0.252 0.409 
0.1 0.1 0.2 0.5 51.1 23.0 0.999 0.999 0.994 1.000 1.000 1.000 1.000 
Scenario 2-3 
0.001 0.002 0.002 0.005 1.5 0.6 0.069 0.119 0.069 0.118 0.008 0.001 0.011 
0.01 0.02 0.02 0.05 5.9 3.2 0.293 0.284 0.170 0.368 0.185 0.110 0.089 
0.1 0.2 0.2 0.5 51.0 28.4 0.986 0.983 0.939 1.000 1.000 0.973 0.409 
Scenario 2-4 
0.001 0.002 0.004 0.008 1.8 0.8 0.096 0.126 0.073 0.158 0.011 0.006 0.007 
0.01 0.02 0.04 0.08 9.0 5.2 0.348 0.326 0.187 0.295 0.219 0.171 0.026 
0.1 0.2 0.4 0.8 81.0 45.2 1.000 1.000 1.000 1.000 1.000 1.000 0.027 
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4.2 Multiplicative assumption 
In this section, we implemented simulations by setting incidence f under the 
multiplicative assumption. The reason for simulations under the multiplicative assumption 
was to examine the false positive rate and sensitivity when the definition of interaction was 
changed. In scenario 3 comparing false positive rate, scenarios (3-1) and (3-2) are the same 
with scenarios (1-1) and (1-2) because they satisfy both the additive assumption and 
multiplicative assumption. In scenario 4 comparing sensitivity, scenarios (4-1), (4-2), and 
(4-3) are equivalent to scenarios (2-1), (2-2), and (2-3) because they also satisfy both the 
additive assumption and multiplicative assumption. It can be shown that satisfying the 
multiplicative assumption will imply satisfying the additive assumption, thus the additive 
model has the lower threshold for incidence f to reach an interaction, 
The detection signals of the multiplicative model mean stronger interactions than those 
of the additive model. By comparison, the additive model can detect the DDI signal earlier. 
The multiplicative model can help determine whether there is stronger evidence of DDI 
after checking DDI with the additive model.
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Table 4. False positive rate in simulation scenario 3
Incidence probability for AE(%) False positive rate 
Ω shrinkage 
method 
𝑋2  statistics method PRR CSS Additive Multiplicative 
𝑓00  𝑓10 𝑓01  𝑓11 g E  Χ𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑=2 Χ𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑=2.6     
Scenario 3-1 
0.005 0.005 0.005 0.005 1.5 1.3 0.006 0.112 0.003 0.086 0.002 0.000 0.063 
0.05 0.05 0.05 0.05 6.0 7.3 0.006 0.004 0.000 0.002 0.004 0.013 0.052 
0.5 0.5 0.5 0.5 51.0 54.8 0.000 0.001 0.000 0.000 0.005 0.028 0.033 
Scenario 3-2 
0.001 0.001 0.005 0.005 1.5 0.9 0.038 0.061 0.028 0.017 0.003 0.002 0.002 
0.01 0.01 0.05 0.05 5.9 6.4 0.024 0.020 0.007 0.014 0.004 0.013 0.028 
0.1 0.1 0.5 0.5 51.0 53.0 0.003 0.002 0.000 0.004 0.002 0.035 0.026 
Scenario 3-3 
0.001 0.002 0.002 0.004 1.4 0.6 0.049 0.091 0.047 0.062 0.004 0.001 0.006 
0.0018 0.003 0.003 0.005 1.5 0.7 0.042 0.075 0.037 0.085 0.006 0.000 0.022 
0.018 0.03 0.03 0.05 6.0 4.4 0.113 0.106 0.049 0.119 0.058 0.034 0.047 
Scenario 3-4 
0.001875 0.003 0.005 0.008 1.8 0.9 0.069 0.107 0.049 0.137 0.015 0.002 0.018 
0.01875 0.03 0.05 0.08 9.0 6.3 0.188 0.170 0.084 0.180 0.117 0.085 0.038 
0.04375 0.05 0.07 0.08 9.0 8.3 0.054 0.048 0.015 0.039 0.019 0.026 0.046 
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Table 5. Sensitivity in simulation scenario 4
Incidence probability for AE(%) Sensitivity 
Ω shrinkage 
method 
𝑋2  statistics method PRR CSS Additive Multiplicative 
𝑓00  𝑓10 𝑓01  𝑓11 g E  Χ𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑=2 Χ𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑=2.6     
Scenario 4-1 
0.001 0.001 0.001 0.005 1.5 0.5 0.080 0.213 0.126 0.261 0.013 0.004 0.040 
0.01 0.01 0.01 0.05 6.0 2.2 0.538 0.541 0.393 0.565 0.496 0.494 0.765 
0.1 0.1 0.1 0.5 50.9 13.0 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
Scenario 4-2 
0.001 0.001 0.002 0.005 1.5 0.5 0.079 0.160 0.091 0.113 0.011 0.003 0.019 
0.01 0.01 0.02 0.05 5.9 3.0 0.369 0.319 0.212 0.380 0.236 0.250 0.410 
0.1 0.1 0.2 0.5 50.9 22.7 1.000 1.000 0.998 1.000 1.000 1.000 1.000 
Scenario 4-3 
0.001 0.002 0.002 0.005 1.5 0.6 0.067 0.112 0.061 0.085 0.007 0.001 0.009 
0.01 0.02 0.02 0.05 6.0 3.2 0.309 0.296 0.176 0.393 0.198 0.112 0.085 
0.1 0.2 0.2 0.5 51.1 28.4 0.988 0.985 0.937 1.000 1.000 0.969 0.398 
Scenario 4-4 
0.0008 0.001 0.003 0.005 1.5 0.5 0.084 0.153 0.096 0.100 0.007 0.002 0.003 
0.008 0.01 0.03 0.05 6.0 3.8 0.207 0.190 0.103 0.134 0.074 0.092 0.087 




We applied DDI signal detection methods to Korea Adverse Event Reporting System 
(KEARS) data from the Korea Institute of Drug Safety and Risk Management (KIDS) in 
2017-2019. Known interaction was derived from a research report published by the Health 
Insurance Review and Assessment Service (HIRA) on the adverse event monitoring system, 
and the list of contraindications of co-medication drugs was derived from KIDS (as of Dec. 
28, 2020). In addition, suspected interaction pairs were selected from the combination of 
drug-drug-AE that has high frequency in KEARS data. 
A total of 1,131,985 reports were taken from the KEARS. Among them, there were 
1656 cases of hyperkalemia and284 cases of QT prolongation. Hyperkalemia is defined as 
an elevation in serum potassium to a value greater than 5 mmol/L (Evans et al., 2005). 
Potassium chloride is prescribed for potassium-deficiency, electrolyte imbalance, and 
digitalis poisoning. Spironolactone is a diuretic. Tactolimus is an intensive 
immunosuppressant agent used to prevent transplant rejection. According to the HIRA 
research report, co-administration of potassium chloride and spironolactone was reported 
to cause hyperkalemia. QT prolongation was defined as a QT interval greater than 450 ms 
in woman and greater than 440 ms in man. Prolongation of the QT interval is associated 
with an increased risk of development of a potentially lethal cardiac arrhythmia called 
torsade de pointes, a risk that increases with the administration of a QT-prolonging drugs 
(Beny Charbit et al., 2006). Domperidone is a drug that increases gastrointestinal motility 
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and is prescribed for indigestion and vomiting. Amiodarone is an antiarrhythmic drug. 
The relative reporting rate for the exposure status of each drug-drug pair was 
summarized in Table 6. The measure of six methods for the six drug-drug-AE combinations 
was summarized in Table 7. In Table 7, “domperidone - amiodarone / QT prolongation” 
which is known interaction, was detected as a potential signal by the 𝛺 method, the chi-
square method, the PRR method, the CSS method, and the additive model. “Domperidone 
- amiodarone” had the small number of reports for the combination (about 18), but its 
reporting proportions were 222.2 per 1000 for domperidone-amiodarone combination. It 
was much larger than the reporting proportion of the other two pairs (53.6 per 1000 for 
potassium chloride - spironolactone, 62.5 per 1000 for tacrolimus - spironolactone). The 
multiplicative showed a positive interaction trend for domperidone - amiodarone 
combination, but it did not show the statistical significance (p-value=0.185).  
“Acetylsalicylic acid - polystyrene sulfonate / hyperkalemia” which is a suspected 
interaction, was detected as a potential signal by the 𝛺 method, the chi-square method, 
and the PRR method. The reporting proportion of “acetylsalicylic acid - polystyrene 
sulfonate” was 47.9 per 1000, the largest of the three suspected interactions. While the 
combination of acetylsalicylic acid and polystyrene sulfonate was not previously known 
interaction, DDI signals were detected among the suspected combinations that has a large 
number of AE reports. However, it is difficult to accept strong evidence of DDI since only 
three of the six methods identified DDI. 
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For known interactions, only one drug-drug pair (domperidone- amiodarone) was 
detected and the other two combinations were not exactly identified. The reason for the 
reduced sensitivity may be that the number of cases is very small because it is rare to 
prescribe combinations that are known to have side effects when taken together.
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Table 6. The proportion of adverse event in the exposure status of each drug-drug pair 
 
 Table 7. The measure of each method applied to drug-drug / adverse events 
  
 
Drug-drug pair Adverse event No A, No B A, No B No A, B A and B 
Known interaction 
Potassium chloride(A)-spironolactone(B) Hyperkalemia 1132/1145114 7/2308 505/4813 12/224 
Tacrolimus(A)-spironolactone(B) Hyperkalemia 1023/1143317 116/4105 515/5005 2/32 
Domperidone(A)-amiodarone(B) QT prolongation 252/1147706 3/2728 25/1533 4/18 
Suspected interaction 
Carvedilol(A)-spironolactone(B) Hyperkalemia 1103/1140660 36/6762 497/4107 20/930 
Acetylsalicylic acid(A)- polystyrene sulfonate(B) Hyperkalemia 1541/1124513 43/25783 50/1704 22/459 
Acetylsalicylic acid(A)-amiodarone(B) QT prolongation 254/1124458 1/25976 25/1285 4/266 
Drug-drug / adverse event 𝛺 𝑋2 PRR CSS Additive Multiplicative 
   PRR025𝐷1𝐷2 max  𝛽3  p-value 𝛽3  p-value 
 Known interaction 
Potassium chloride-spironolactone / Hyperkalemia -1.780 -2.532 21.607 93.542 0.190 -0.053 0.001 -1.793 0.000 
Tacrolimus-spironolactone / Hyperkalemia -2.848 -1.250 11.371 93.542 0.010 -0.678 0.116 -3.951 0.000 
Domperidone-amiodarone / QT prolongation 1.062 5.741 382.197 57.637 3.096 0.205 0.037 1.001 0.185 
 Suspected interaction 
Carvedilol-spironolactone / Hyperkalemia -3.135 -8.942 9.786 93.542 0.086 -0.104 0.000 -3.433 0.000 
Acetylsalicylic acid- polystyrene sulfonate/ Hyperkalemia 0.072 2.143 22.412 19.160 0.735 0.018 0.090 0.294 0.317 
Acetylsalicylic acid-amiodarone / QT prolongation -1.749 -0.736 23.223 57.637 0.188 -0.004 0.614 1.511 0.183 
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6. Conclusion and discussion 
As the number of patients with chronic disease becomes more common, the co-
prescription of multiple drugs has increased. Therefore, it has become more important to 
identify combinations of drugs that have side effects through post-market drug safety 
surveillance. In this article, we examined statistical methodologies for DDI signal detection. 
Of the six methods, the 𝛺 shrinkage method and the chi-square method show the best 
performance. The 𝛺  shrinkage method and the chi-square method with threshold=2 
controlled the false positive rate below 0.05 and had high sensitivity in most scenarios. The 
chi-square method is especially effective when AE has a small number of reports (g<2). 
The chi-square method with threshold=2.6 and the additive model are conservative 
methods. They rigorously control the FPR, but they had lower sensitivity than the  𝛺 
shrinkage method and the chi-square method with threshold=2.  
An important consideration is that spontaneous reporting system databases may result 
in bias due to underreporting. Since underreporting information is not included in the 
collected data, it cannot be considered. Thus, it is likely to have a significant impact on 
DDI signal detection. Furthermore, the six methods introduced in this paper identify DDI 
using an interaction signal indicator defined by an equation. Therefore, there is a limitation 
in that the definition of a true DDI signal depends on the measure of each methods. 
The aforementioned methods have the advantage of being easy to apply and easy to 
calculate, but the sole use of individual method is not adequate. It is recommended to use 
the other methods at the same time. Also, pharmacological mechanisms for drug-drug 
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interactions should be considered. The DDI signal detection considering clinical aspects 
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 국 문 요 약 
많은 선행연구에서 두 가지 약물을 함께 복용함으로 인해 발생하는 약물 
부작용을 탐지하는 방법을 연구하였다. 약물 부작용으로 의심되는 신호는 시판 후 
의약품 안전 감시를 통하여 발견될 수 있다. 시판 후 의약품 안전 감시는 부작용 
보고와 의약품 처방 정보에 대한 자발적 보고 데이터에 기반한다. 약물간 상호작용 
신호 탐지방법에 대한 대부분의 선행 연구는 이러한 자발적 보고 데이터에 각 
방법들을 적용하고 각 방법들 간의 성능을 비교하였다. 본 논문에서는 다양한 
조건하에서 시물레이션을 수행하여 여러 방법들 간의 성능을 평가한다. 이를 통해 각 
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